Plus Therapeutics, SpectronRx announce manufacturing partnership

Plus Therapeutics (PSTV) and SpectronRx announced the signing of a Manufacturing Services Agreement, MSA, for the production of Rhenium Obisbemeda, an innovative radiotherapy for CNS cancers, including leptomeningeal metastases and recurrent glioblastoma. Under this strategic partnership, SpectronRx will utilize its state-of-the-art facilities to produce late-stage clinical and commercial supplies of Rhenium Obisbemeda. SpectronRx currently has more than 170,000 sq ft of radiopharmaceutical contract development and manufacturing, rCDMO,) space and 150 employees across five locations. It provides services to 29 countries, working hand-in-hand with more than 31 pharmaceutical companies to develop and produce life-saving nuclear medicines, including those radiolabeled with 186Re. By joining forces with Plus Therapeutics, SpectronRx aims to further its mission of advancing nuclear medicine.